Active Trials: ATN-224

Primary

• In patients with biochemically relapsed, hormone-naïve prostate cancer, determine the proportion who have not had prostate specific antigen (PSA) progression at 24 weeks for two dose levels of ATN-224. The lower dose level (30 mg) is hypothesized to be antiangiogenic and the higher dose level (300 mg) is hypothesized to have direct anti-tumor activity.

Secondary

• Establish the safety of the two dose levels of ATN-224
  
  
• For each dose level, determine:
  
  
  • Proportion of patients with a 50% reduction from baseline of PSA confirmed by a second PSA value at least 28 days later
    
    
  • Change in PSA doubling time (PSA-DT) from baseline
    
    
  • Maximal % decrease in PSA after treatment
    
    
  • Time to PSA progression (as defined by this protocol)
    
    
  • 24-week rate of metastases
    
    
  • Effect of ATN-224 treatment on levels of Cu,Zn-superoxide dismutase (SOD1) in red blood cells